SCHOTT Pharma Achieves Strong Growth in H1 FY 2023, Expands High-Value Solutions Portfolio
SCHOTT Pharma, a renowned pioneer in pharmaceutical drug containment solutions and delivery systems, continues to make significant strides in the global pharma industry. In the first half of FY 2023, the company achieved an impressive 13.2% year-on-year growth, generating EUR 449 million in sales. Notably, the company’s EBITDA increased by 16.6% to EUR 132 million, resulting in a margin of 29.4%.
SCHOTT Pharma’s strategy of prioritizing high-value solutions has yielded remarkable results, with these products now accounting for a significant 45% share of sales. The company’s commitment to capturing emerging opportunities in GLP-1 treatments, mRNA drugs, originator biologics, and biosimilars has contributed to sustained growth and expanded market reach.
To meet the surging demand for injectables, SCHOTT Pharma is actively expanding its production capacity for high-value products. The company has already established a state-of-the-art facility in Southern Germany for prefillable polymer syringes and is significantly increasing capacity for ready-to-use vials in the United States. Moreover, construction has commenced for a new manufacturing hub dedicated to prefillable glass syringes in Hungary.
SCHOTT Pharma remains at the forefront of innovation, continually investing in research and development to deliver cutting-edge products. The company recently expanded its portfolio within the high-value solutions segment, introducing SCHOTT TOPPAC® freeze prefillable polymer syringes. This groundbreaking solution enables the safe storage and transportation of deep-cold drugs, including mRNA vaccines, at extremely low temperatures, meeting the unique requirements of the pharmaceutical industry.
SCHOTT Pharma plays a pivotal role in delivering high-quality solutions for GLP-1 drugs that effectively manage blood sugar levels and combat diabetes and obesity. With long-term contracts secured with key market players, the company supplies prefillable glass syringes and cartridges critical for the administration of these life-changing medications.
Operating primarily in the injectables market, SCHOTT Pharma anticipates substantial growth within this sector, outpacing the overall performance of the pharmaceutical industry. By strategically focusing on injectable products, the company capitalizes on the rising demand and positions itself for continued success in a rapidly expanding market.
Source: SCHOTT Pharma with additional information added by GlassBalkan
